Interviews

Javier Cortes, MD, PhD, discusses results from the PHERGain study, evaluating chemotherapy de-escalation strategies in HER2-positive early breast cancer, presented at the 2023 ASCO Annual Meeting.

On site at ASCO 2023, Dr Lars Henrik Jensen shares results from the phase 3 NeoCol trial evaluating the addition of neoadjuvant chemotherapy to initial surgery for patients with locally advanced colon cancer.

At the 2023 ASCO Annual Meeting, Jason Luke, MD, shares results from the protocol-specified final distant metastasis-free survival analysis of KEYNOTE-716, evaluating adjuvant pembrolizumab among patients with stage IIIB and IIIC resected...

Sara Tolaney shares the final overall survival analysis of the phase 3 TROPiCS-02 trial, evaluating sacituzumab govitecan in pretreated metastatic HR-positive breast cancer, which was presented at the 2023 ASCO Annual Meeting

At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.

At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...

At the 2023 ASCO GU Cancers Symposium, Kyle Rose, MD, presents results from a prospective study investigating urinary tumor DNA as a surrogate for minimal residual disease among patients with NMIBC undergoing repeat TURBT.

Neal Shore, MD, shares insights about the recent FDA approval of darolutamide plus ADT and docetaxel for patients with metastatic hormone-sensitive prostate cancer and the data that led to this approval.

Welela Tereffe, MD, MPH, highlights MD Anderson Cancer Center’s impact on the future of cancer care and immunotherapy research, as the center celebrates its 80th anniversary.

In an interview with Oncology Learning Network, Saad Z. Usmani, MD, spoke on the findings and clinical significance of a phase 1 study on teclistamab, a BCMA and CD3 bispecific antibody, in patients with R/R MM.